



29 April 2021

Incanthera plc

("Incanthera" or the "Company")

Appointment of Company Secretary

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology is pleased to announce the appointment of Suzanne Brocks to Company Secretary with effect from 28th April 2021.

Suzanne joined Incanthera in 2014 as Head of Communications, a role she has held prior to and during the Company's flotation on to the AQSE Growth Market, and she will continue to hold this role in addition to her appointment as Company Secretary.

In addition to public and investor relations, Suzanne has been significantly involved in the administrative affairs of the Company including the coordination of statutory and regulatory matters. The position as Company Secretary will reflect her involvement across these areas of the Company, in complement to her role overseeing internal and public facing corporate communications.

The Company is delighted Suzanne has accepted this position and wishes her well in her enhanced role.

For further enquiries:

Incanthera plc
www.incanthera.com

Tim McCarthy, Chairman +44 (0) 7831 675747
tim.mccarthy@incanthera.com

Simon Ward, Chief Executive Officer +44 (0) 7747 625506
simon.ward@incanthera.com

Suzanne Brocks, Head of Communications +44 (0) 7776 234600
suzanne.brocks@incanthera.com

Aquis Exchange Corporate Adviser: +44 (0) 20 7213 0880
Cairn Financial Advisers LLP
Jo Turner/James Lewis/Mark Rogers

Broker: +44 (0) 20 3815 8880
Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob Pountney

Notes to Editors

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

@incantherapl